Get the Stockscreener App
11.43
2.88%
0.32
Forte Biosciences Inc stock is traded at $11.43, with a volume of 58,277.
It is up +2.88% in the last 24 hours and up +9.59% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$11.11
Open:
$11.31
24h Volume:
58,277
Relative Volume:
0.60
Market Cap:
$75.25M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-10.99
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
-1.21%
1M Performance:
+9.59%
6M Performance:
+4.10%
1Y Performance:
+43.32%
1-Day Range:
$10.54
$11.80
1-Week Range:
$10.54
$13.63
52-Week Range:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
11.43 | 145.47M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Visual analytics tools that track Forte Biosciences Inc. performanceLong Setup & Weekly Top Performers Watchlists - Newser
Forte Biosciences, Inc.'s (NASDAQ:FBRX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 9.2% Over the Past Week - 富途牛牛
Will a bounce in Forte Biosciences Inc. offer an exitJuly 2025 Outlook & Technical Pattern Alert System - Newser
What to expect from Forte Biosciences Inc. in the next 30 days2025 Performance Recap & Detailed Earnings Play Strategies - Newser
Published on: 2025-08-20 02:11:18 - Newser
Intraday pattern recognizer results for Forte Biosciences Inc.July 2025 Fed Impact & Fast Gain Swing Trade Alerts - Newser
Is this a good reentry point in Forte Biosciences Inc.2025 Price Targets & Technical Pattern Based Buy Signals - Newser
Candlestick signals on Forte Biosciences Inc. stock todayEarnings Recap Report & Capital Efficient Trade Techniques - Newser
Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential - MSN
Published on: 2025-08-19 15:21:54 - Newser
Using Ichimoku Cloud for Forte Biosciences Inc. technicals2025 Earnings Impact & Expert Approved Momentum Trade Ideas - Newser
Using Python tools to backtest Forte Biosciences Inc. strategies2025 Risk Factors & Growth-Oriented Investment Plans - Newser
Can you recover from losses in Forte Biosciences Inc.Quarterly Trade Summary & Daily Entry Point Alerts - Newser
Forte Biosciences Reports Q2 2025 Financial Results - TipRanks
Forte Biosciences shares surge 14.81% intraday after Guggenheim analyst initiates coverage with a buy rating and $75 price target. - AInvest
Forte Biosciences: Guggenheim initiates Buy rating, sets PT at $75. - AInvest
Guggenheim initiates Forte Biosciences stock with Buy rating on autoimmune therapy potential - Investing.com Nigeria
Published on: 2025-08-18 04:36:24 - Newser
Using data filters to optimize entry into Forte Biosciences Inc.Market Performance Summary & Precise Swing Trade Alerts - Newser
Long term hold vs stop loss in Forte Biosciences Inc.Options Play & Weekly Return Optimization Plans - Newser
Real time social sentiment graph for Forte Biosciences Inc.Market Rally & Long-Term Growth Stock Strategies - Newser
What indicators show strength in Forte Biosciences Inc.2025 Price Targets & Scalable Portfolio Growth Ideas - Newser
Real time alert setup for Forte Biosciences Inc. performance2025 Market Overview & Weekly High Return Opportunities - Newser
Forte Biosciences Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Performance Report & Long-Term Capital Growth Strategies - Newser
Chardan Capital Reaffirms Buy Rating for Forte Biosciences (NASDAQ:FBRX) - Defense World
Automated trading signals detected on Forte Biosciences Inc.Trade Ideas & Verified Technical Signals - Newser
Is Forte Biosciences Inc.’s ROIC above industry average2025 Market Outlook & Advanced Technical Signal Analysis - thegnnews.com
What MACD and RSI say about Forte Biosciences Inc.July 2025 Short Interest & Stepwise Entry/Exit Trade Alerts - Newser
How to forecast Forte Biosciences Inc. trends using time seriesCEO Change & Smart Allocation Stock Reports - Newser
Reversal indicators forming on Forte Biosciences Inc. stockWeekly Profit Report & Daily Chart Pattern Signals - Newser
Applying chart zones and confluence areas to Forte Biosciences Inc.2025 Performance Recap & Fast Entry High Yield Tips - Newser
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,151 |
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):